Pharmafile.com’s weekly COVID-19 news round-up
June 10, 2021The past week has seen lots of vaccine-related news, Pfizer-BioNTech has expanded its COVID-19 vaccine study in children under 12, …
NICE release new guidance on rheumatoid arthritis treatment
June 10, 2021NICE, biosimilar, rheumatoid arthritis
NICE has today published final draft guidance for the treatment of moderate rheumatoid arthritis in patients who have not responded …
SMC approves nintedanib for patients with chronic lung disease
June 10, 2021The Scottish Medicines Consortium (SMC) has approved nintedanib for NHSScotland for the treatment of adult patients with chronic fibrosing interstitial …
COVID chaos: Survey reveals global oncology trial disruptions
June 10, 2021data, oncology
The pandemic has had a widespread impact across the healthcare industry and the world, however, a recent global survey from …
Pfizer to expand COVID vaccine study in children under 12
June 10, 2021COVID-19, Pfizer, Vaccine
Pfizer has announced that it will begin large-scale testing of its COVID-19 vaccine after selecting a lower dose of the …
Phase III trial supports the potential use of Cabometyx for thyroid cancer
June 8, 2021Manufacturing and Production
Ipsen and Exelixis have announced detailed results from the Phase III COSMIC-311 pivotal trial of Cabozantinib in patients with previously …
FDA approves first new Alzheimer’s drug in two decades
June 8, 2021Manufacturing and Production
Biogen’s controversial new drug, aducanumab, has been accepted by the FDA, making it the first Alzheimer’s drug to be approved …
MHRA approves venetoclax as acute myeloid leukemia treatment
June 8, 2021Manufacturing and Production EC, EU, MHRA, leukemia
The MHRA has announced its approval for AbbVie’s venetoclax, in combination with a hypomethylating agent, for the treatment of newly …
MSD announce new data from advanced renal cell carcinoma trial
June 8, 2021Manufacturing and Production MSD, rcc
Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …
New NICE recommendation for Astellas prostate cancer drug
June 8, 2021Manufacturing and Production Astellas, NICE, prostate cancer
A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …
Astronomy & cancer: Researchers join forces to study CUP
June 7, 2021Sales and Marketing oncology
Astronomers from Durham University have joined forces with cancer researchers to advance the diagnosis and treatment of cancer of unknown …
UK vaccination update
June 7, 2021Sales and Marketing
With 21 June fast approaching, and the Delta variant rising in the UK, here’s the latest vaccine update. Firstly, the …
AstraZeneca vs GSK: Cancer drug court battle could cost hundreds of millions
June 7, 2021Sales and Marketing AstraZeneca, GSK, court
AstraZeneca has launched a court case against Glaxo Smith Kline (GSK), in a claim that could reach hundreds of millions …
MHRA confirms registration of Avacta’s lateral flow test
June 7, 2021Sales and Marketing COVID-19, EU, MHRA, lateral flow test
Avacta has announced that the MHRA has confirmed registration of the AffiDX SARS-CoV-2 antigen lateral flow test, which allows the …
Regeneron’s COVID-19 antibody EUA reduced to lower dose by FDA
June 7, 2021Sales and Marketing
The FDA has updated the Emergency Use Authorisation (EUA) for Regeneron Pharmaceuticals’ COVID-19 antibody cocktail, REGEN-COV, halving the dose from …
Pharmafile.com’s top 10 news stories of the week
June 4, 2021Medical Communications
Among our ten most-read stories this week: NICE rejects risdiplam for treating spinal muscular atrophy; The EU wants to Fine …
Novartis’s 177Lu-PSMA-617 reduces prostate cancer death risk by 38%
June 4, 2021Medical Communications
Novartis’s 177Lu-PSMA-617 has shown to significantly improve overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer …
BMS announce new positive data from oesophageal cancer study
June 4, 2021Medical Communications Cancer, oncology
Bristol Myers Squibb (BMS) has announced results from the Phase III CheckMate -648 trial in which nivolumab plus chemotherapy and …
Phase III trial shows Olaparib reduces breast cancer recurrence by 42%
June 4, 2021Medical Communications
Results from OlympiA’s Phase III trial has shown that its Olaparib (Lynparza) in the adjuvant treatment of patients with germline …
J&J’s Tremfya sees positive results for post-TNFi psoriatic arthritis
June 4, 2021Medical Communications J&J, JJ
Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, in post-tumour necrosis factor (TNF) …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
